Pharmacogenetics of asthma.

Area of Science:

• Pharmacogenomics
• Respiratory Medicine
• Molecular Biology

Background:

• Interindividual variability in drug response is increasingly linked to genetic differences.
• Understanding genetic variations in drug targets is crucial for personalized medicine.
• Asthma treatment efficacy can be influenced by patient-specific genetic profiles.

Purpose of the Study:

• To review current knowledge on genetic variability in key airway targets for asthma treatment.
• To identify genes with significant polymorphic variation relevant to asthma pharmacogenomics.
• To highlight areas requiring further investigation in airway target genetic screening.

Main Methods:

• Literature review of studies on genetic variability in asthma treatment targets.
• Analysis of polymorphic variation in genes encoding muscarinic receptors, beta2-adrenoceptors, and 5-lipoxygenase.
• Assessment of the contribution of genetic variability to treatment response.

Main Results:

• Some asthma targets, like muscarinic M2 and M3 receptors, exhibit limited polymorphic variation.
• Genes such as beta2-adrenoceptor and 5-lipoxygenase demonstrate extensive genetic variation.
• This genetic variability in key targets may partially explain differences in asthma treatment response.

Conclusions:

• Genetic variability in specific airway targets, notably beta2-adrenoceptor and 5-lipoxygenase, plays a role in asthma treatment response.
• Further screening for polymorphic variation in other key airway targets is warranted.
• Pharmacogenomic insights into these targets can advance personalized asthma management.